SCHEMBL15904223

SCHEMBL15904223

[C]#Cc1ccc(C(=O)Nc2ccc(O)c(C(=O)O)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT6 Q8N6T7 3/20 0.58
▸ KMT2A Q03164 3/20 0.54
▸ PKM P14618 2/20 0.54
▸ MAPT P10636 3/20 0.50
▸ AKR1C3 P42330 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ SIRT3 Q9NTG7 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ AKR1C2 P52895 1/20 0.50
▸ AKR1C1 Q04828 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ KDM4C Q9H3R0 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ TOP1 P11387 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15903931 0.89 KMT2A (0.69) SIRT6KMT2APKMMAPTMEN1
SCHEMBL13805528 0.84 SIRT6 (0.65) SIRT6KMT2APKMMAPTAKR1C3
SCHEMBL1129948 0.82 KMT2A (0.77) SIRT6KMT2APKMMAPTAKR1C3
SCHEMBL10759208 0.81 MITF (0.64) SIRT6KMT2APKMMAPTAKR1C3
SCHEMBL10758235 0.80 SIRT6 (0.64) SIRT6KMT2APKMMAPTMEN1
SCHEMBL23796858 0.78 SIRT6 (0.58) SIRT6KMT2APKMMAPTAKR1C3
SCHEMBL30418835 0.78 SIRT6 (0.58) SIRT6KMT2APKMMAPTAKR1C3
SCHEMBL16471399 0.78 SIRT6 (0.58) SIRT6KMT2APKMMAPTAKR1C3
SCHEMBL31376926 0.78 SIRT6 (0.62) SIRT6KMT2APKMMAPTAKR1C3
SCHEMBL15904226 0.77 HPSE (0.67) KMT2APKMMEN1POLBNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed
EP-2948450-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals, Inc. (US) 2015-12-02 — — EP disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO SIRT6 2001/4885KMT2A 1886/4885PKM 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback